M08.452 Pauciarticular juvenile rheumatoid arthritis, left hip

Name of the Condition

• Pauciarticular Juvenile Rheumatoid Arthritis, Left Hip

Summary

Pauciarticular juvenile rheumatoid arthritis is a subtype of juvenile idiopathic arthritis characterized by inflammation in four or fewer joints during the first six months of disease onset. The "left hip" designation specifies the left hip joint as the site of involvement. This condition primarily affects children and adolescents, with symptoms including joint pain, swelling, and stiffness localized to the hip. Systemic features may be present but are less prominent than in other subtypes.

Causes

The exact cause is unknown, but it is believed to be an autoimmune disorder where the immune system mistakenly attacks healthy joint tissues. Genetic factors and environmental triggers may contribute to disease development, though specific triggers are not well-defined.

Risk Factors

• Age (most commonly diagnosed in children under 16).
• Female gender (higher prevalence, especially in those with ANA positivity).
• Positive antinuclear antibody (ANA) test, which increases risk of uveitis.
• Family history of autoimmune diseases.

Symptoms

• Joint pain, swelling, and stiffness in the left hip, often worse in the morning.
• Reduced range of motion in the affected hip.
• Possible limping or difficulty bearing weight on the affected side.
• Systemic symptoms (e.g., fever, rash) in some cases.

Diagnosis

Diagnosis involves a combination of clinical evaluation, medical history, and diagnostic tests. Physical examination assesses joint involvement, while blood tests (e.g., inflammatory markers) and imaging (e.g., X-rays or MRI) may be used to confirm hip inflammation. Exclusion of other conditions is critical for accurate diagnosis.

Treatment Options

Treatment focuses on reducing inflammation, preserving joint function, and managing symptoms. Options may include nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and intra-articular corticosteroid injections. Biologic agents or disease-modifying antirheumatic drugs (DMARDs) may be considered for persistent disease.

Prognosis and Follow-Up

Prognosis varies; many children achieve remission, but some may develop chronic joint damage. Regular follow-up with a rheumatologist is essential to monitor disease activity, adjust treatment, and screen for complications like uveitis. Early intervention improves long-term outcomes.

Complications

• Chronic joint damage or deformity in the left hip.
• Uveitis (eye inflammation), particularly in ANA-positive patients.
• Growth disturbances or leg length discrepancies.
• Reduced mobility or functional impairment.

Lifestyle & Prevention

• Maintain a balanced diet to support joint health.
• Engage in low-impact exercises (e.g., swimming) to preserve mobility.
• Use assistive devices (e.g., crutches) if needed to reduce hip stress.
• Protect the hip from injury during physical activity.

When to Seek Professional Help

Seek care if symptoms worsen, new joint involvement occurs, or systemic signs (e.g., fever, rash) develop. Prompt evaluation is critical for managing inflammation and preventing complications.

Tips for Medical Coders

Document the specific joint (left hip) and confirm pauciarticular involvement (four or fewer joints) within six months of onset. Ensure clinical notes support the diagnosis and site specificity to justify code assignment.